DYAX News 6.73 Dyax Corp (DYAX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Dyax Corp (DYAX) 6.73 $DYAX

Dyax Corp. to Host First Quarter 2014 Earnings Call and Webcast
Business Wire - Thu Apr 17, 7:00AM CDT
Dyax Corp. (NASDAQYAX) will host a webcast and conference call, including an open question and answer session, Wednesday, April 30, 2014. During the call, management will discuss the Company's financial results for the first quarter 2014 as well as progress regarding its key value drivers - the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio.

Dyax Corp. Announces Appointment of Todd Bazemore as Chief Commercial Officer
Business Wire - Wed Apr 16, 7:01AM CDT
Dyax Corp. (NASDAQ: DYAX) announced today the appointment of Todd Bazemore as Executive Vice President and Chief Commercial Officer. Mr. Bazemore will be responsible for leading Dyax's commercial organization which currently markets KALBITOR(R) (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older.

The Recent Performance of 'Baker Brother Biotech Stocks' is Awful
at The Street - Tue Apr 15, 11:23AM CDT
Healthcare's most closely followed hedge fund is losing money during the biotech bubble burst.

Downtrend Call Working As Dyax Stock Falls 15.0% (DYAX)
Comtex SmarTrend(R) - Mon Apr 14, 9:18AM CDT
SmarTrend identified a Downtrend for Dyax (NASDAQYAX) on March 24th, 2014 at $8.61. In approximately 3 weeks, Dyax has returned 14.98% as of today's recent price of $7.32.

Dyax wins FDA approval to include use of KALBITOR for treating HAE acute attacks in patients 12 years of age and older
M2 - Fri Apr 04, 6:08AM CDT
Biopharmaceutical company Dyax (NasdaqGMYAX) revealed on Thursday the receipt of US Food and Drug Administration (FDA) for an expansion of the indication of KALBITOR (ecallantide) to include patients 12 years of age and older in the treatment of acute hereditary angioedema (HAE) attacks.

Dyax Receives FDA Approval to Expand Use of KALBITOR(R) (ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema to Patients 12 Years of Age and Older
Business Wire - Thu Apr 03, 3:05PM CDT
Dyax Corp. (NASDAQYAX) today announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication for KALBITOR (ecallantide), a peptide inhibitor of plasma kallikrein used in the treatment of acute hereditary angioedema (HAE) attacks, to include patients 12 years of age and older. With this approval, KALBITOR is the first and only subcutaneous therapy available to treat acute attacks of HAE in patients 12 years of age and older. KALBITOR is also the only therapy that is not purified from human plasma that has been approved to treat this patient group.

Dyax Corp. to Participate in the 13th Annual Needham Healthcare Conference
Business Wire - Wed Apr 02, 1:00PM CDT
Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the 13th Annual Needham Healthcare Conference being held April 8-9, 2014 at the Westin Grand Central Hotel in New York City. Gustav Christensen, President and Chief Executive Officer of Dyax, will present on Tuesday, April 8 at 2:20 PM (ET). Mr. Christensen will provide a corporate update on the Company's key value drivers - the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio.

Dyax Corp. (DYAX) in Focus: Stock Up 6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:44AM CDT
Dyax Corp. was a big mover last session, as the company saw its shares rally nearly 6% on the day.

Dyax Corporation (DYAX) Marked As A Dead Cat Bounce Stock
at The Street - Thu Mar 27, 9:07AM CDT
Trade-Ideas LLC identified Dyax Corporation (DYAX) as a "dead cat bounce" (down big yesterday but up big today) candidate

Dyax reports full exercise of 1.2m additional shares in underwriters' option
M2 - Wed Mar 26, 3:01AM CDT
Biopharmaceutical company Dyax (NasdaqGMYAX) said on Tuesday that the underwriters of its public offering have exercised in full their option to purchase another 1,200,000 common shares.

Dyax Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
Business Wire - Tue Mar 25, 3:05PM CDT
Dyax Corp. (NASDAQ: DYAX) today announced that the underwriters of its previously announced public offering have exercised in full their option to purchase an additional 1,200,000 shares of Dyax's common stock at a price to the public of $9.25 per share, less customary underwriting discounts and commissions. The net proceeds of approximately $10.4 million from the exercise of the option brings the aggregate net proceeds from the offering to approximately $80.0 million, after deducting the underwriting discount and other estimated offering expenses payable by Dyax. The additional shares were delivered to the underwriters on March 25, 2014.

Shares of DYAX Up 13.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 20, 10:06AM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQYAX) on January 10th, 2014 at $8.17. In approximately 2 months, Dyax has returned 13.78% as of today's recent price of $9.29.

Dyax prices public offering of 8m common shares
M2 - Mon Mar 17, 9:39AM CDT
US-based biopharmaceutical company Dyax (NasdaqGMYAX) said on Friday that it has priced an underwritten public offering of 8m shares of its common stock at a price of USD9.25 per share.

Nasdaq stocks posting largest percentage decreases
AP - Fri Mar 14, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:

Why Dyax Corp. Shares Dipped
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 14, 12:24PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Dyax , a biopharmaceutical company focused...

Dyax Announces Pricing of $74 Million Public Offering of Common Stock
Business Wire - Fri Mar 14, 8:05AM CDT
Dyax Corp. (NASDAQ: DYAX) today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock, offered at a price to the public of $9.25 per share. The gross proceeds to Dyax from this offering are expected to be $74 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Dyax. The offering is expected to close on or about March 19, 2013, subject to customary closing conditions.

Dyax to sell common stock in planned public offering
M2 - Fri Mar 14, 3:50AM CDT
Biopharmaceutical company Dyax (NasdaqGMYAX) said on Thursday that it plans to launch its common stock in a proposed underwritten public offering.

Dyax Announces Proposed Public Offering of Common Stock
Business Wire - Thu Mar 13, 3:02PM CDT
Dyax Corp. (NASDAQ: DYAX) today announced that it is offering to sell shares of its common stock in a proposed underwritten public offering. All shares to be sold in the offering are being sold by Dyax. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Jefferies LLC is acting as the sole book-running manager for the offering. Cowen and Company, LLC is acting as the co-lead manager, with Wedbush PacGrow Life Sciences, Needham & Company, LLC, and Oppenheimer & Co. Inc. acting as co-managers.

27.7% Return Seen to Date on SmarTrend Dyax Call (DYAX)
Comtex SmarTrend(R) - Wed Mar 12, 5:05PM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQYAX) on January 10th, 2014 at $8.17. In approximately 2 months, Dyax has returned 27.74% as of today's recent price of $10.43.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Colon Cleanse Advice Deserves a Careful Read First

Updated Category News Views 93

Wellness copy can sound harmless right up until it blurs comfort guidance with health guidance. HelloNation’s feature on what to expect after a colon cleanse, drawing on Suzanne Childre of Gentle Wellness Center in Santa Monica, lays out a fairly familiar recovery script: drink water, rest, eat lightly, expect some bowel changes, and do not panic over a little fatigue....

Continue Reading
Refund Delays Are Becoming an E-Commerce Sales Risk

Updated Category News Views 176

A returned jacket can turn into a household cash-flow problem faster than retailers seem willing to admit. Seel's new survey lands at an awkward moment for online merchants: shoppers are not merely annoyed by slow refunds; many are budgeting around them. Among 1,921 U.S. adults who had shopped online in the prior six months, 63% said waiting for a retailer to receive a...

Continue Reading
First Grade Literacy Push Deserves a Harder Look Now

Updated Category News Views 130

A reading gap can become a concrete wall before anyone bothers measuring it. That is the uncomfortable point behind Ignite Reading's First Grade Promise, and it deserves more attention than another polished education announcement usually gets. At a Nov. 5 Convene 2026 gathering in Boston, 56 district and literacy leaders from six states focused on getting children reading...

Continue Reading
PG&E's $456 Million Interim Hike Faces a New Test Soon

Updated Category News Views 51

A utility can call a charge interim, but households still see the bill arrive in full. That is why the California Public Utilities Commission's unanimous approval of $456 million in interim rate recovery for Pacific Gas & Electric has landed with such rotten timing. The money is set to begin flowing from customers on January 1, 2027, while major questions about PG&E's...

Continue Reading
Lecanemab's Alpha-Syn Signal Deserves a Cooler Head

Updated Category News Views 45

Mixed pathology is where Alzheimer's investing gets uncomfortably real, and this new lecanemab readout is a decent reminder that a drug can show promise without settling the argument. Eisai and Biogen presented a Clarity AD cerebrospinal-fluid substudy at CTAD 2026 examining people with early Alzheimer's disease who also tested positive for alpha-synuclein pathology. The...

Continue Reading
CATL Builds Türkiye Battery Service Muscle in Istanbul

Updated Category News Views 43

Battery warranties look mighty impressive until a pack needs work on a Tuesday morning and nobody nearby can touch it. CATL's new NING SERVICE Experience Center in Istanbul goes straight at that unglamorous problem. The facility, announced November 19, 2026, is described as Türkiye's first dedicated battery depot repair center and an integrated sales-and-service hub. It...

Continue Reading
Compounded Peptides Demand Clearer FDA Status Answers

Updated Category News Views 73

Peptide talk has gotten muddled enough to make plain English feel revolutionary. The central point in the HelloNation article featuring wellness expert Andres Giraldo is straightforward: a compounded peptide is not FDA approved in the same product-specific manner as a commercially manufactured drug. That is not a small semantic wrinkle, and it should not be buried beneath...

Continue Reading
Lowe's Dec. 9 Conference Puts Strategy on the Clock

Updated Category News Views 148

A Calendar Entry With Real Weight December 9 is not earnings day, but it is the sort of date shareholders ought to circle anyway. Lowe's plans to hold its 2026 Analyst and Investor Conference at 8 a.m. Eastern time in New York City, with a live webcast available for those not sitting in the room. For owners of NYSE:LOW, these gatherings can be more useful than the usual...

Continue Reading
IT Tech Packaging's Going-Concern Warning Lands Hard

Updated Category News Views 76

A paper maker can survive plenty of ugly quarters; it cannot casually shrug off an auditor questioning whether it can keep operating. That is the cold part of IT Tech Packaging's Nov. 19 disclosure. Its newly filed Form 10-K for the year ended Dec. 31, 2025 carries a “Material Uncertainty Related to Going Concern” paragraph from Audit Alliance LLP. Nobody should dress...

Continue Reading
AIM Academy Accreditation Signals a Broader Quality Push

Updated Category News Views 50

Early-childhood education does not hand out many clean, easily comparable scorecards, which is precisely why AIM Academy’s new Cognia recognition deserves a closer look. The Alabama provider has earned Cognia Initial Accreditation, while its Pike Road center received Accreditation with Merit after its Initial Accreditation Review. That is not a revenue event, not a...

Continue Reading

Top 5 Most Recently Viewed Articles

Alfa Laval Enhances Gulf Coast Support with La Porte Expansion

Updated Category News Views 183

Alfa Laval Strengthens Local Support with La Porte Service Center Alfa Laval, a world leader in heat transfer, separation, and fluid handling, is proud to announce the expansion of its Service Center in La Porte, Texas. This newly expanded facility is set to bolster the support for the Gulf Coast's industrial community, demonstrating the company’s commitment to local...

Continue Reading
AgEagle Aerial Systems Achieves Impressive Q1 Financial Gains

Updated Category News Views 209

AgEagle Aerial Systems Achieves Strong Financial Results A remarkable transformation is underway at AgEagle Aerial Systems Inc. (NYSE: UAVS), a key player in unmanned aerial systems (UAS) and sensor technology. The company has announced financial results for the first quarter of fiscal year 2025, showcasing a sharp recovery and robust performance in various financial...

Continue Reading
Empowering Future Leaders: The 6th Student Research Competition

Updated Category News Views 259

Empowering Future Leaders: The 6th Student Research Competition The Fixed Income Analysts Society (FIASI), in partnership with Fordham University's Center for Research in Contemporary Finance and the O'Shea Center for Credit Analysis and Investment, is excited to announce the launch of its highly anticipated 6th Annual FIASI – Gabelli School Student Research...

Continue Reading
LALO Tequila Unveils Unique 2025 High Proof Blanco Expression

Updated Category News Views 414

Introducing the 2025 High Proof Blanco Tequila LALO Tequila proudly presents its latest creation, the 2025 High Proof Blanco, marking a significant chapter in its celebrated line of limited-edition spirits. Scheduled just in time for Hispanic Heritage Month, this release embodies the brand’s strong cultural roots while embracing modern advancements in the tequila...

Continue Reading
TaskUs, Inc. to Reveal Q3 2024 Earnings on November 7

Updated Category News Views 95

TaskUs, Inc. to Reveal Financial Results for Q3 2024 TaskUs, Inc. (Nasdaq: TASK), a prominent leader in providing outsourced digital services and advanced customer experience, will disclose its third quarter 2024 financial results following the market's closure on November 7. Conference Call and Webcast Details Management will conduct a conference call and webcast at 5:00...

Continue Reading